{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T23:53:44Z","timestamp":1781481224107,"version":"3.54.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Handok Inc","award":["2021-31-1083"],"award-info":[{"award-number":["2021-31-1083"]}]},{"DOI":"10.13039\/501100008005","name":"Yonsei University College of Medicine","doi-asserted-by":"crossref","award":["6-2016-0116"],"award-info":[{"award-number":["6-2016-0116"]}],"id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"crossref"}]},{"name":"University-Industry Foundation Grant","award":["2015-31-0723"],"award-info":[{"award-number":["2015-31-0723"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-43479-8","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T20:04:16Z","timestamp":1776715456000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rosuvastatin attenuates tubulointerstitial fibrosis by targeting the HOXA13 USAG1 BMP7 pathway"],"prefix":"10.1038","volume":"16","author":[{"given":"Donghwan","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Jeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-hyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoon Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunwook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Jong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeong Cheon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"43479_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41392-023-01379-7","volume":"8","author":"R Huang","year":"2023","unstructured":"Huang, R., Fu, P. & Ma, L. Kidney fibrosis: From mechanisms to therapeutic medicines. Signal Transduct. Target. Ther. 8, 129. https:\/\/doi.org\/10.1038\/s41392-023-01379-7 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"43479_CR2","doi-asserted-by":"publisher","first-page":"174","DOI":"10.23876\/j.krcp.22.159","volume":"42","author":"C Wang","year":"2023","unstructured":"Wang, C., Li, S. W., Zhong, X., Liu, B. C. & Lv, L. L. An update on renal fibrosis: From mechanisms to therapeutic strategies with a focus on extracellular vesicles. Kidney Res. Clin. Pract. 42, 174\u2013187. https:\/\/doi.org\/10.23876\/j.krcp.22.159 (2023).","journal-title":"Kidney Res. Clin. Pract."},{"key":"43479_CR3","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrneph.2016.48","volume":"12","author":"XM Meng","year":"2016","unstructured":"Meng, X. M., Nikolic-Paterson, D. J. & Lan, H. Y. TGF-\u03b2: The master regulator of fibrosis. Nat. Rev. Nephrol. 12, 325\u2013338. https:\/\/doi.org\/10.1038\/nrneph.2016.48 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"43479_CR4","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/ki.2010.88","volume":"77","author":"O Garc\u00eda-S\u00e1nchez","year":"2010","unstructured":"Garc\u00eda-S\u00e1nchez, O., L\u00f3pez-Hern\u00e1ndez, F. J. & L\u00f3pez-Novoa, J. M. An integrative view on the role of TGF-\u03b2 in the progressive tubular deletion associated with chronic kidney disease. Kidney Int. 77, 950\u2013955. https:\/\/doi.org\/10.1038\/ki.2010.88 (2010).","journal-title":"Kidney Int."},{"key":"43479_CR5","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1681\/asn.V7122495","volume":"7","author":"AA Eddy","year":"1996","unstructured":"Eddy, A. A. Molecular insights into renal interstitial fibrosis. J. Am. Soc. Nephrol. 7, 2495\u20132508. https:\/\/doi.org\/10.1681\/asn.V7122495 (1996).","journal-title":"J. Am. Soc. Nephrol."},{"key":"43479_CR6","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1681\/asn.2010121308","volume":"22","author":"W Qin","year":"2011","unstructured":"Qin, W. et al. TGF-\u03b2\/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J. Am. Soc. Nephrol. 22, 1462\u20131474. https:\/\/doi.org\/10.1681\/asn.2010121308 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"43479_CR7","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1101\/gad.9.22.2795","volume":"9","author":"AT Dudley","year":"1995","unstructured":"Dudley, A. T., Lyons, K. M. & Robertson, E. J. A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye. Genes Dev. 9, 2795\u20132807. https:\/\/doi.org\/10.1101\/gad.9.22.2795 (1995).","journal-title":"Genes Dev."},{"key":"43479_CR8","first-page":"164","volume":"54","author":"R Ivanac-Jankovi\u0107","year":"2015","unstructured":"Ivanac-Jankovi\u0107, R. et al. BMP-7 Protein expression is downregulated in human diabetic nephropathy. Acta Clin Croat 54, 164\u2013168 (2015).","journal-title":"Acta Clin Croat"},{"key":"43479_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-11-31","volume":"11","author":"CP Bramlage","year":"2010","unstructured":"Bramlage, C. P. et al. Bone morphogenetic protein (BMP)-7 expression is decreased in human hypertensive nephrosclerosis. BMC Nephrol. 11, 31. https:\/\/doi.org\/10.1186\/1471-2369-11-31 (2010).","journal-title":"BMC Nephrol."},{"key":"43479_CR10","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.64.s87.16.x","author":"S Klahr","year":"2003","unstructured":"Klahr, S. & Morrissey, J. Obstructive nephropathy and renal fibrosis: The role of bone morphogenic protein-7 and hepatocyte growth factor. Kidney Int. Suppl. https:\/\/doi.org\/10.1046\/j.1523-1755.64.s87.16.x (2003).","journal-title":"Kidney Int. Suppl."},{"key":"43479_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147897","volume":"11","author":"DK Singla","year":"2016","unstructured":"Singla, D. K., Singla, R. & Wang, J. BMP-7 treatment increases M2 macrophage differentiation and reduces inflammation and plaque formation in Apo E-\/- mice. PLoS ONE 11, e0147897. https:\/\/doi.org\/10.1371\/journal.pone.0147897 (2016).","journal-title":"PLoS ONE"},{"key":"43479_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1046\/j.1523-1755.2002.00103.x","volume":"61","author":"SE Gould","year":"2002","unstructured":"Gould, S. E., Day, M., Jones, S. S. & Dorai, H. BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells1. Kidney Int. 61, 51\u201360. https:\/\/doi.org\/10.1046\/j.1523-1755.2002.00103.x (2002).","journal-title":"Kidney Int."},{"key":"43479_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cells8101130","author":"F Dituri","year":"2019","unstructured":"Dituri, F., Cossu, C., Mancarella, S. & Giannelli, G. The interactivity between TGF\u03b2 and BMP signaling in organogenesis, fibrosis, and cancer. Cells https:\/\/doi.org\/10.3390\/cells8101130 (2019).","journal-title":"Cells"},{"key":"43479_CR14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1440-1797.2005.00334.x","volume":"10","author":"W Wang","year":"2005","unstructured":"Wang, W., Koka, V. & Lan, H. Y. Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology (Carlton) 10, 48\u201356. https:\/\/doi.org\/10.1111\/j.1440-1797.2005.00334.x (2005).","journal-title":"Nephrology (Carlton)"},{"issue":"Suppl 1","key":"43479_CR15","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1681\/ASN.V13suppl_1s14","volume":"13","author":"J Morrissey","year":"2002","unstructured":"Morrissey, J. et al. Bone morphogenetic protein-7 improves renal fibrosis and accelerates the return of renal function. J. Am. Soc. Nephrol. 13(Suppl 1), S14-21 (2002).","journal-title":"J. Am. Soc. Nephrol."},{"key":"43479_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/sj.ki.5002626","volume":"73","author":"M Tanaka","year":"2008","unstructured":"Tanaka, M. et al. Expression of BMP-7 and USAG-1 (a BMP antagonist) in kidney development and injury. Kidney Int. 73, 181\u2013191. https:\/\/doi.org\/10.1038\/sj.ki.5002626 (2008).","journal-title":"Kidney Int."},{"key":"43479_CR17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1172\/jci25445","volume":"116","author":"M Yanagita","year":"2006","unstructured":"Yanagita, M. et al. Uterine sensitization-associated gene-1 (USAG-1), a novel BMP antagonist expressed in the kidney, accelerates tubular injury. J. Clin. Invest. 116, 70\u201379. https:\/\/doi.org\/10.1172\/jci25445 (2006).","journal-title":"J. Clin. Invest."},{"key":"43479_CR18","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.bbrc.2004.02.075","volume":"316","author":"M Yanagita","year":"2004","unstructured":"Yanagita, M. et al. USAG-1: A bone morphogenetic protein antagonist abundantly expressed in the kidney. Biochem. Biophys. Res. Commun. 316, 490\u2013500. https:\/\/doi.org\/10.1016\/j.bbrc.2004.02.075 (2004).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"43479_CR19","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9752139","volume":"2021","author":"X Li","year":"2021","unstructured":"Li, X., Yue, W., Feng, G. & Li, J. Uterine sensitization-associated gene-1 in the progression of kidney diseases. J. Immunol. Res. 2021, 9752139. https:\/\/doi.org\/10.1155\/2021\/9752139 (2021).","journal-title":"J. Immunol. Res."},{"key":"43479_CR20","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jama.2022.13044","volume":"328","author":"CM Mangione","year":"2022","unstructured":"Mangione, C. M. et al. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force Recommendation Statement. JAMA 328, 746\u2013753. https:\/\/doi.org\/10.1001\/jama.2022.13044 (2022).","journal-title":"JAMA"},{"key":"43479_CR21","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1161\/circulationaha.119.044282","volume":"141","author":"SS Virani","year":"2020","unstructured":"Virani, S. S., Smith, S. C. Jr., Stone, N. J. & Grundy, S. M. Secondary prevention for atherosclerotic cardiovascular disease: Comparing recent US and European guidelines on dyslipidemia. Circulation 141, 1121\u20131123. https:\/\/doi.org\/10.1161\/circulationaha.119.044282 (2020).","journal-title":"Circulation"},{"key":"43479_CR22","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/ki.2008.231","volume":"74","author":"LF Fried","year":"2008","unstructured":"Fried, L. F. Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease. Kidney Int. 74, 571\u2013576. https:\/\/doi.org\/10.1038\/ki.2008.231 (2008).","journal-title":"Kidney Int."},{"key":"43479_CR23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1172\/jci16421","volume":"110","author":"JK Liao","year":"2002","unstructured":"Liao, J. K. Isoprenoids as mediators of the biological effects of statins. J. Clin. Invest. 110, 285\u2013288. https:\/\/doi.org\/10.1172\/jci16421 (2002).","journal-title":"J. Clin. Invest."},{"key":"43479_CR24","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1093\/ndt\/gfh859","volume":"20","author":"JM Vieira","year":"2005","unstructured":"Vieira, J. M. et al. Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction. Nephrol. Dial. Transplant. 20, 1582\u20131591. https:\/\/doi.org\/10.1093\/ndt\/gfh859 (2005).","journal-title":"Nephrol. Dial. Transplant."},{"key":"43479_CR25","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/labinvest.2012.71","volume":"92","author":"Y Hamasaki","year":"2012","unstructured":"Hamasaki, Y. et al. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor simvastatin ameliorates renal fibrosis through HOXA13-USAG-1 pathway. Lab. Invest. 92, 1161\u20131170. https:\/\/doi.org\/10.1038\/labinvest.2012.71 (2012).","journal-title":"Lab. Invest."},{"key":"43479_CR26","doi-asserted-by":"publisher","first-page":"6843","DOI":"10.1074\/jbc.M610775200","volume":"282","author":"WM Knosp","year":"2007","unstructured":"Knosp, W. M., Saneyoshi, C., Shou, S., B\u00e4chinger, H. P. & Stadler, H. S. Elucidation, quantitative refinement, and in vivo utilization of the HOXA13 DNA binding site. J. Biol. Chem. 282, 6843\u20136853. https:\/\/doi.org\/10.1074\/jbc.M610775200 (2007).","journal-title":"J. Biol. Chem."},{"key":"43479_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000484962","volume":"193","author":"M Fiorentino","year":"2018","unstructured":"Fiorentino, M., Grandaliano, G., Gesualdo, L. & Castellano, G. Acute kidney injury to chronic kidney disease transition. Contrib. Nephrol. 193, 45\u201354. https:\/\/doi.org\/10.1159\/000484962 (2018).","journal-title":"Contrib. Nephrol."},{"key":"43479_CR28","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1080\/0886022x.2022.2126790","volume":"44","author":"J Zhang","year":"2022","unstructured":"Zhang, J. et al. Effects of contralateral nephrectomy timing and ischemic conditions on kidney fibrosis after unilateral kidney ischemia-reperfusion injury. Ren. Fail. 44, 1568\u20131584. https:\/\/doi.org\/10.1080\/0886022x.2022.2126790 (2022).","journal-title":"Ren. Fail."},{"key":"43479_CR29","doi-asserted-by":"publisher","DOI":"10.1080\/0886022x.2024.2336128","volume":"46","author":"Q Yang","year":"2024","unstructured":"Yang, Q., Su, S., Luo, N. & Cao, G. Adenine-induced animal model of chronic kidney disease: Current applications and future perspectives. Ren. Fail. 46, 2336128. https:\/\/doi.org\/10.1080\/0886022x.2024.2336128 (2024).","journal-title":"Ren. Fail."},{"key":"43479_CR30","doi-asserted-by":"publisher","first-page":"F286","DOI":"10.1152\/ajprenal.00021.2019","volume":"317","author":"J Wei","year":"2019","unstructured":"Wei, J. et al. New mouse model of chronic kidney disease transitioned from ischemic acute kidney injury. Am. J. Physiol. Renal Physiol. 317, F286-f295. https:\/\/doi.org\/10.1152\/ajprenal.00021.2019 (2019).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"43479_CR31","doi-asserted-by":"publisher","first-page":"F1098","DOI":"10.1152\/ajprenal.00199.2018","volume":"315","author":"Y Fu","year":"2018","unstructured":"Fu, Y. et al. Rodent models of AKI-CKD transition. Am. J. Physiol. Renal Physiol. 315, F1098-f1106. https:\/\/doi.org\/10.1152\/ajprenal.00199.2018 (2018).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"43479_CR32","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/sj.ki.5002366","volume":"72","author":"M Fujii","year":"2007","unstructured":"Fujii, M. et al. Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db\/db mice. Kidney Int. 72, 473\u2013480. https:\/\/doi.org\/10.1038\/sj.ki.5002366 (2007).","journal-title":"Kidney Int."},{"key":"43479_CR33","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.14448","volume":"8","author":"CJ Leader","year":"2020","unstructured":"Leader, C. J., Kelly, D. J., Sammut, I. A., Wilkins, G. T. & Walker, R. J. Spironolactone mitigates, but does not reverse, the progression of renal fibrosis in a transgenic hypertensive rat. Physiol. Rep. 8, e14448. https:\/\/doi.org\/10.14814\/phy2.14448 (2020).","journal-title":"Physiol. Rep."},{"key":"43479_CR34","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ahj.2004.06.027","volume":"149","author":"S John","year":"2005","unstructured":"John, S., Schneider, M. P., Delles, C., Jacobi, J. & Schmieder, R. E. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am. Heart J. 149, 473. https:\/\/doi.org\/10.1016\/j.ahj.2004.06.027 (2005).","journal-title":"Am. Heart J."},{"key":"43479_CR35","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1161\/01.str.32.4.980","volume":"32","author":"S Amin-Hanjani","year":"2001","unstructured":"Amin-Hanjani, S. et al. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 32, 980\u2013986. https:\/\/doi.org\/10.1161\/01.str.32.4.980 (2001).","journal-title":"Stroke"},{"key":"43479_CR36","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/s0021-9150(03)00197-7","volume":"169","author":"HJ Mulder","year":"2003","unstructured":"Mulder, H. J. et al. Improvement of serum oxidation by pravastatin might be one of the mechanisms by which endothelial function in dilated coronary artery segments is ameliorated. Atherosclerosis 169, 309\u2013315. https:\/\/doi.org\/10.1016\/s0021-9150(03)00197-7 (2003).","journal-title":"Atherosclerosis"},{"key":"43479_CR37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10557-007-6025-3","volume":"21","author":"V Chopra","year":"2007","unstructured":"Chopra, V., Choksi, P. U. & Cavusoglu, E. Beyond lipid lowering: The anti-hypertensive role of statins. Cardiovasc. Drugs Ther. 21, 161\u2013169. https:\/\/doi.org\/10.1007\/s10557-007-6025-3 (2007).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"43479_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1542-4758.2012.00716.x","author":"C-C Chang","year":"2012","unstructured":"Chang, C.-C. et al. Simvastatin downregulates the expression of hepcidin and erythropoietin in HepG2 cells. Hemodial. Int. https:\/\/doi.org\/10.1111\/j.1542-4758.2012.00716.x (2012).","journal-title":"Hemodial. Int."},{"key":"43479_CR39","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1177\/0091270010386607","volume":"51","author":"MA Brookhart","year":"2011","unstructured":"Brookhart, M. A., Solomon, D. H., Glynn, R. J. & Ridker, P. M. Effect of rosuvastatin on hemoglobin levels in patients with anemia and low-grade inflammation: A post hoc analysis of the JUPITER trial. J. Clin. Pharmacol. 51, 1483\u20131487. https:\/\/doi.org\/10.1177\/0091270010386607 (2011).","journal-title":"J. Clin. Pharmacol."},{"key":"43479_CR40","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg6194","volume":"9","author":"J Ahn","year":"2023","unstructured":"Ahn, J., Lee, S. & Won, S. Possible link between statin and iron deficiency anemia: A South Korean nationwide population-based cohort study. Sci. Adv. 9, eadg6194. https:\/\/doi.org\/10.1126\/sciadv.adg6194 (2023).","journal-title":"Sci. Adv."},{"key":"43479_CR41","doi-asserted-by":"publisher","first-page":"288","DOI":"10.4252\/wjsc.v8.i9.288","volume":"8","author":"T Tsujimura","year":"2016","unstructured":"Tsujimura, T., Idei, M., Yoshikawa, M., Takase, O. & Hishikawa, K. Roles and regulation of bone morphogenetic protein-7 in kidney development and diseases. World J. Stem Cells 8, 288\u2013296. https:\/\/doi.org\/10.4252\/wjsc.v8.i9.288 (2016).","journal-title":"World J. Stem Cells"},{"key":"43479_CR42","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s00467-008-0818-x","volume":"23","author":"M Zeisberg","year":"2008","unstructured":"Zeisberg, M. & Kalluri, R. Reversal of experimental renal fibrosis by BMP7 provides insights into novel therapeutic strategies for chronic kidney disease. Pediatr. Nephrol. 23, 1395\u20131398. https:\/\/doi.org\/10.1007\/s00467-008-0818-x (2008).","journal-title":"Pediatr. Nephrol."},{"key":"43479_CR43","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1159\/000079177","volume":"97","author":"Y Ikeda","year":"2004","unstructured":"Ikeda, Y. et al. Exogenous bone morphogenetic protein-7 fails to attenuate renal fibrosis in rats with overload proteinuria. Nephron Exp. Nephrol. 97, e123-135. https:\/\/doi.org\/10.1159\/000079177 (2004).","journal-title":"Nephron Exp. Nephrol."},{"key":"43479_CR44","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1681\/asn.2004100835","volume":"16","author":"MR Davies","year":"2005","unstructured":"Davies, M. R., Lund, R. J., Mathew, S. & Hruska, K. A. Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J. Am. Soc. Nephrol. 16, 917\u2013928. https:\/\/doi.org\/10.1681\/asn.2004100835 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"43479_CR45","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1093\/ndt\/gfk010","volume":"21","author":"M Zeisberg","year":"2006","unstructured":"Zeisberg, M. Bone morphogenic protein-7 and the kidney: Current concepts and open questions. Nephrol. Dial. Transplant. 21, 568\u2013573. https:\/\/doi.org\/10.1093\/ndt\/gfk010 (2006).","journal-title":"Nephrol. Dial. Transplant."},{"issue":"7","key":"43479_CR46","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/nm888","volume":"9","author":"M Zeisberg","year":"2003","unstructured":"Zeisberg, M. et al. BMP-7 counteracts TGF-\u03b21\u2013induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat. Med. 9(7), 964\u2013968. https:\/\/doi.org\/10.1038\/nm888 (2003).","journal-title":"Nat. Med."},{"key":"43479_CR47","doi-asserted-by":"publisher","first-page":"8094","DOI":"10.1074\/jbc.M413102200","volume":"280","author":"M Zeisberg","year":"2005","unstructured":"Zeisberg, M., Shah, A. A. & Kalluri, R. Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J. Biol. Chem. 280, 8094\u20138100. https:\/\/doi.org\/10.1074\/jbc.M413102200 (2005).","journal-title":"J. Biol. Chem."},{"key":"43479_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2015.00114","volume":"6","author":"RX Li","year":"2015","unstructured":"Li, R. X., Yiu, W. H. & Tang, S. C. Role of bone morphogenetic protein-7 in renal fibrosis. Front. Physiol. 6, 114. https:\/\/doi.org\/10.3389\/fphys.2015.00114 (2015).","journal-title":"Front. Physiol."},{"key":"43479_CR49","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1093\/ndt\/gfp604","volume":"25","author":"EH Bae","year":"2010","unstructured":"Bae, E. H. et al. Renoprotective effect of rosuvastatin in DOCA-salt hypertensive rats. Nephrol. Dial. Transplant. 25, 1051\u20131059. https:\/\/doi.org\/10.1093\/ndt\/gfp604 (2010).","journal-title":"Nephrol. Dial. Transplant."},{"key":"43479_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58030425","author":"GH Heeba","year":"2022","unstructured":"Heeba, G. H., Ali, M. A. M. & El-Sheikh, A. A. K. Rosuvastatin induces renal HO-1 activity and expression levels as a main protective mechanism against STZ-induced diabetic nephropathy. Medicina (Kaunas) https:\/\/doi.org\/10.3390\/medicina58030425 (2022).","journal-title":"Medicina (Kaunas)"},{"key":"43479_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-95140-1","volume":"11","author":"JC D\u00edaz-Zagoya","year":"2021","unstructured":"D\u00edaz-Zagoya, J. C. et al. Effects of high rosuvastatin doses on hepatocyte mitochondria of hypercholesterolemic mice. Sci. Rep. 11, 15809. https:\/\/doi.org\/10.1038\/s41598-021-95140-1 (2021).","journal-title":"Sci. Rep."},{"key":"43479_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35944-z","volume":"14","author":"TS Huang","year":"2023","unstructured":"Huang, T. S. et al. Long-term statins administration exacerbates diabetic nephropathy via ectopic fat deposition in diabetic mice. Nat. Commun. 14, 390. https:\/\/doi.org\/10.1038\/s41467-023-35944-z (2023).","journal-title":"Nat. Commun."},{"key":"43479_CR53","doi-asserted-by":"publisher","first-page":"F357","DOI":"10.1152\/ajprenal.00542.2009","volume":"298","author":"HC Park","year":"2010","unstructured":"Park, H. C. et al. Postobstructive regeneration of kidney is derailed when surge in renal stem cells during course of unilateral ureteral obstruction is halted. Am. J. Physiol. Renal Physiol. 298, F357-364. https:\/\/doi.org\/10.1152\/ajprenal.00542.2009 (2010).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"43479_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-015-0012-6","volume":"6","author":"HY Choi","year":"2015","unstructured":"Choi, H. Y. et al. Mesenchymal stem cell-derived microparticles ameliorate peritubular capillary rarefaction via inhibition of endothelial-mesenchymal transition and decrease tubulointerstitial fibrosis in unilateral ureteral obstruction. Stem Cell Res. Ther. 6, 18. https:\/\/doi.org\/10.1186\/s13287-015-0012-6 (2015).","journal-title":"Stem Cell Res. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43479-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43479-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43479-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T23:48:02Z","timestamp":1781480882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43479-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["43479"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-43479-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4775630\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"21 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18478"}}